Quick math, because this club should put money back in your pocket. Founding members pay $10 a month. Your member code takes 10% off at Vial-Science.com from day one. After 90 days, it goes to 20%. Where you break even each month: - 10% code: spend $100, save $10. Membership covered. - 20% code: spend $50, save $10. Covered. On a $250 order: - 10% saves $25. That's 2.5 months of membership. - 20% saves $50. That's 5 months. Two more things: - Your code works on sale prices too, including the holiday sale running through Dec 4. - The $10 founding price is only for the first 20 members. 7 are in. After that, new members pay $29.99 a month. Your code is in Member Perks in the Classroom. (Yes, I own Vial-Science. That's exactly why members get the best price.)

It's been a week since HHS said it won't go after licensed pharmacies that compound six peptides: BPC-157, TB-500, Epitalon, KPV, MOTS-c and Semax. A lot has happened since. 1. Telehealth is moving fast. On Nov 5, Amble Health announced it now offers all six through online visits. You fill out a health assessment, a licensed provider decides, and a state-licensed compounding pharmacy ships it. Hims & Hers already told investors this summer that it was testing BPC-157 so it could move as soon as the rules allowed. 2. Wall Street noticed. Hims stock jumped about 5% on the HHS news. 3. The pushback is still loud. The AMA came out against the policy again this week. Their argument is that there isn't enough safety data yet. 4. You get a say. The policy is a draft, and public comments close Nov 13. Anyone can comment. Search "HHS-OASH-2026-0496" on regulations.gov, or open the notice on federalregister.gov and click "Submit a formal comment." Tell them what access means to you. Short and respectful works best. What this means for us: more legal ways to get these six, through a prescription. It's a draft and it could still change. And wherever your peptides come from, quality still matters. Read the COA before you use anything. The Classroom shows you how. Would you go the telehealth route, or stick with what you're doing now? Tell me below.

On Wednesday, October 28, the Department of Health and Human Services issued an interim policy directing the FDA not to take enforcement action against licensed compounding pharmacies that make six peptides. The six are BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax. This is enforcement discretion, not approval. None of the six is FDA approved for any use, and the policy does not approve them. What it means is that state-licensed 503A compounding pharmacies, federal facilities, and licensed physicians can compound these peptides without facing federal enforcement, provided they follow the policy's conditions: ingredients from FDA-registered manufacturers, verification of the peptide's chemical identity, and reporting of compounded products, serious adverse events, and quality issues to the FDA and the states. A prescription is still required, since compounding is done for an individual patient. Some background on how we got here. In 2023, the FDA restricted compounding of these peptides over safety concerns. In July 2026, the FDA's Pharmacy Compounding Advisory Committee voted to recommend adding six of seven reviewed peptides to the 503A Bulks List, while FDA scientists recommended against it. HHS then chose enforcement discretion rather than a formal rule adding them to the list. The decision came from HHS, and reporting indicates FDA scientific staff had limited input and largely opposed it. HHS says the move advances patient choice and freedom and offers a controlled alternative to gray market peptides sold online. Critics, including the American Medical Association, say the peptides have not undergone the testing required of FDA-approved drugs. What this does not change: - It does not legalize research-use-only peptides sold online. The policy covers licensed compounders, not online RUO retailers. The FDA sent warning letters to online RUO vendors as recently as August. - It is not permanent. No timeframe was given for how long the discretion lasts, HHS says it may revisit the policy if safety or quality problems emerge, and final rulemaking is still pending. Public comments are open for two weeks.